Almost without fail, one of the first questions a patient with a meningioma asks is, “What caused my tumor?” Many possible etiologic factors have been proposed during the last century. Solid epidemiologic evidence for most of these factors has proven fleeting. The availability and application of molecular biology techniques to investigate meningioma tumorigenesis, however, has revealed many insights into how these tumors develop and progress on the cellular level. Not only will further understanding of meningioma tumorigenesis answer the patient's “first” question, it may also lead to a better molecular classification to complement the current morphologic classification of meningiomas (see Chapter 5) and, of course, hopefully lead to novel therapeutic approaches to treat these tenacious tumors. Somewhat confounding efforts to elucidate the cause of meningioma is a lack of universal agreement on the cell of origin for all meningiomas. Most meningiomas likely arise from mesodermal arachnoid cap cells normally found at the apex of arachnoid granulations.1,2 Cleland, in 1846, is credited with first correlating these cells to meningioma formation.3 They are found adjacent to major venous sinuses where the majority of meningiomas occur, and the normal arachnoid cap cells histologically resemble meningothelial meningiomas. However, meningiomas may occur at unusual sites such as choroid plexus,4,5 within bone,6,7 or, very rarely, outside the neural axis.8 For these tumors a different cell of origin may be possible, or they may arise from heterotopic meningothelial rests.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
O'Rahilly R, Muller F. The meninges in human development. J Neuropathol Exp Neurol 1986;45:588–608.
Drummond KJ, Zhu JJ, Black PM. Meningiomas: updating basic science, management, and outcome. Neurologist 2004;10:113–130.
Cleland J. Description of two tumours adherent to the deep surface of the dura-mater. Glasgow Med J 1864;11:148–159.
Nakamura M, Roser F, Bundschuh O, et al. Intraventricular meningiomas: a review of 16 cases with reference to the literature. Surg Neurol 2003;59:491–504.
Criscuolo GR, Symon L. Intraventricular meningioma. A review of 10 cases of the National Hospital, Queen Square (1974– 1985) with reference to the literature. Acta Neurochir 1986;83:83–91.
Crawford TS, Kleinschmidt-DeMasters BK, Lillehei KO. Primary intraosseous meningioma. Case report. J Neurosurg 1995;83:912–915.
Lang FF, Macdonald OK, Fuller GN, DeMonte F. Primary extradural meningiomas: a report on nine cases and review of the literature from the era of computerized tomography scanning. J Neurosurg 2000;93:940–950.
Shuangshoti S. Primary meningiomas outside the central nervous system. In: Al Mefty O, ed. Meningiomas. New York: Raven, 1991:107–128.
Radhakrishnan K, Mokri B, Parisi JE, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995;37:67–73.
CBTRUS. Statistical Report: Primary brain tumors in the United States, 1997–2001. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2004.
Cushing H. Intracranial Tumors. Notes Upon a Series of Two Thousand Verified Cases. Springfield, IL: Charles C Thomas, 1932.
Grant FC. A study of the results of surgical treatment in 2326 consecutive patients with brain tumors: the national survey of intracranial neoplasms. Neurology 1956;32:219–226.
Zimmerman HM. Brain tumors: their incidence and classification in man and their experimental production. Ann NY Acad Sci 1969;159:337–359.
Schoenberg GS, Christine BW, Whisnant JP. The descriptive epidemiology of primary intracranial neoplasms: The Connecticut experience. Am J Epidemiol 1976;104:499–510.
Kurland LT, Schoenberg BS, Annegers JF, et al. The incidence of primary intracranial neoplasms in Rochester, Minnesota, 1935–1977. Ann NY Acad Sci 1982;381:6–16.
Preston-Martin S, Henderson BE, Peters JM. Descriptive epidemiology of central nervous system neoplasms in Los Angeles County. Ann NY Acad Sci 1982;381:202–208.
Fogelholm R, Uutela T, Murros K. Epidemiology of central nervous system neoplasms: a regional survey in central Finland. Acta Neurol Scand 1984;69:129–136.
Walker AE, Robins H, Weinfeld FD. Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 1985;32:219–226.
Sutherland GR, Florell R, Louw D, et al. Epidemiology of primary intracranial neoplasms in Manitoba, Canada. Can J Neurol Sci 1987;14:586–592.
Kuratsu J, Ushio Y. Epidemiological study of primary intracra-nial tumors in elderly people. J Neurol Neurosurg Psychiatry 1997;63:116–118.
Kirsch M, Santarius T, Black P. Molecular biology of meningio-mas and peripheral nerve sheath tumors. In: Raffel C, Harsh G, eds. The Molecular Basis of Neurosurgical Disease. Baltimore: Congress of Neurological Surgeons, 1996:126–145.
Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol 1993;15:75–77.
Carroll R, Glowacka D, Dashner K, Black P. Progesterone and glucocorticoid receptor activation in meningiomas. Cancer Res 1993;53:1312–1316.
Carroll R, Zhang J, Dashner K, et al. Androgen receptor expression in meningiomas. J Neurosurg 1995;82:453–460.
Wigertz A, Lonn S, Mathiesen T, et al. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006;164:629–636.
Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg 2003;99:848–853.
Schrell U, Fahlbusch R, Adams E, et al. Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors. J Clin Endocrinol Metab 1990;71:1669–1671.
Carroll RS, Schrell UM, Zhang J, et al. Dopamine D1, dopamine D2, and prolactin receptor messenger ribnucleic acid expression by the polymerase chain reaction in human meningiomas. Neu-rosurgery 1996;38:367–375.
Schulz S, Pauli SU, Schulz S, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 2000;6:1865–1874.
Friend K, Radinsky R, McCutcheon I. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 1999;91:93–99.
Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 2004;363:1535–1543.
Giordano C, Lamouche M. Meningiomes en Cote D'Ivoire. Afr J Med Sci 1973;4:249–263.
Odeku EL, Adeloye A. Cranial meningiomas in the Nigerian Africans. Afr J Med Sci 1973;4:275–287.
Manfredonia M. Tumors of the nervous system in the African in Eritrea (Ethiopia). Afr J Med Sci 1973;4:383–387.
Levy LF. Brain tumors in Malawi, Rhodesia and Zambia. Afr J Med Sci 1973;4:393–397.
Cushing H, Eisenhardt L. Meningiomas: their classification, regional behaviour, life history, and surgical end results. Springfield, IL: Charles C Thomas, 1938.
Preston-Martin S, Pogoda JM, Schlehofer B, et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int J Epidemiol 1998;27:579–586.
Phillips LE, Koepsell TD, van Belle G, et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 2002;58:1849–1852.
Parker H, Kernohan J. The relation of injury and glioma of the brain. J Am Med Assoc 1931;97:535–539.
Choi N, Schuma L, Gullen W. Epidemiology of primary central nervous system neoplasms II. Case-control study. Am J Epidemiol 1970;91:467–485.
Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996;29:197–205.
Inskip PD, Mellemkjaer L, Gridley G, Olsen JH. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998;9:109–116.
Annegars JF, Laws ER Jr, Kurland LT, Grabow JD. Head trauma and subsequent brain tumors. Neurosurgery 1979;4:203–206.
Eddy BE, Borman GS, Grubbs GE, Young RD. Identification of the oncogenic substance in rhesus monkey kidney cell culture as simian virus 40. Virology 1962;17:65–75.
Gerber P, Kirschstein RL. SV40-induced ependymomas in newborn hamsters. I. Virus-tumor relationships. Virology 1962;18:582–588.
Brinster RL, Chen HY, Messing A, et al. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984;37:367–379.
Pinkert CA, Brinster RL, Palmiter RD, et al. Tumorigenesis in transgenic mice by a nuclear transport-defective SV40 large T-antigen gene. Virology 1987;160:169–175.
Weiss AF, Portmann R, Fischer H, et al. Simian virus 40-related antigens in three human meningiomas with defined chromosomal loss. Proc Natl Acad Sci USA 1975;72:609–613.
Weiss AF, Zang KD, Birkmayer GD, Miller F. SV40 related papova-viruses in human meningiomas. Acta Neuropathol (Berl) 1976;34:171–174.
Scherneck S, Lubbe L, Geissler E, et al. Detection of simian virus 40 related T-antigen in human meningiomas. Zentralbl Neurochir 1979;40:121–130.
Zimmermann W, Schernick S, Geissler E, Nisch G. Demonstration of SV 40-related tumour antigen in human meningiomas by different hamster SV 40-T-antisera. Acta Virol 1981;25(4):199–204.
Ibelgaufts H, Jones KW. Papovavirus-related RNA sequences in human neurogenic tumours. Acta Neuropathol (Berl) 1982;56:118–122.
Arrington AS, Moore MS, Butel JS. SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus. Onco-gene 2004;23(12):2231–2235.
Weggen S, Bayer TA, von Deimling A, et al. Low frequency of SV40, JC and BK polyomavirus sequences in human medul-loblastomas, meningiomas and ependymomas. Brain Pathol 2000;10:85–92.
Sabatier J, Uro-Coste E, Benouaich A, et al. Immunodetec-tion of SV40 large T antigen in human central nervous system tumours. J Clin Pathol 2005;58:429–431.
Rollison DE, Utaipat U, Ryschkewitsch C, et al. Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. Int J Cancer 2005;113:769–774.
Poltermann S, Schlehofer B, Steindorf K, et al. Lack of association of herpesviruses with brain tumors. J Neurovirol 2006;12:90–99.
Independent Expert Group on Mobile Phones. Mobile Phones and Health. Chilton: National Radiological Protection Board, 2000.
Valberg PA. Radio frequency radiation (RFR): the nature of exposure and carcinogenic potential. Cancer Causes Control 1997;8:323–332.
Hardell L, Nasman A, Pahlson A, et al. Use of cellular telephones and the risk of brain tumors: a case-control study. Int J Oncol 1999;15:113–116.
Dreyer NA, Loughlin JE, Rothman KJ. Cause-specific mortality in cellular phone users. JAMA 1999;282:1814–1816.
Muscat JE, Malkin MG, Thompson S, et al. Handheld cellular telephone use and risk of brain cancer. JAMA 2000;284:3001–3007.
Inskip PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. N Engl J Med 2001;344:79–86.
Johansen C, Boice JD Jr, McLaughlin JK, Olsen JH. Cellular telephones and cancer—a nationwide cohort study in Denmark. J Natl Cancer Inst 2001;93:203–207.
Auvinen A, Hietanen M, Luukkonen R, Koskela R-S. Brain tumors and salivary gland cancers among cellular telephone users. Epidemiology 2002;13:356–359.
Lonn S, Ahlbom A, Hall P, et al. Long-term mobile phone use and brain tumor risk. Am J Epidemiol 2005;161:526–535.
United Nations Scientific Committee on the effects of atomic radiation (UNSCEAR). Sources and effects of ionizing radiation. UNSCEAR 2000. Report to the General Assembly, with scientific annexes. New York: United Nations, 2000.
Berg G, Spallek J, Schuz J, et al. Occupational exposure to radiofrequency/microwave radiation and the risk of brain tumors: Interphone Study Group, Germany. Am J Epidemiol 2006;164:538–548.
Longstreth WT Jr, Dennis LK, McGuire VM, et al. Epidemiology of intracranial meningioma. Cancer 1993;72:639–648.
Beller AJ, Feinsod M, Sahar A. The possible relationship between small dose irradiation to the scalp and intracranial meningiomas. Neurochirurgia 1972;15:135–143.
Giaquinto S, Massi G, Ricolfi A, Vitali S. On six cases of radiation meningiomas from the same community. Ital J Neurol Sci 1984;5:173–175.
Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: exprience at the Mount Sinai Hospital and review of the literature. J Neurousurg 1991;75:564–574.
Soffer D, Pittaluga S, Feiner M, Beller AJ. Intracranial menin-giomas following low-dose irradiation to the head. J Neurosurg 1983;59:1048–1053.
Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D. Radiation-induced meningioma: a descriptive study of 253 cases. J Neuro-surg 2002;97:1078–1082.
Modan B, Baidatz D, Mart H, et al. Radiation-induced head and neck tumours. Lancet 1974;1:277–279.
Werner A, Modan B, Davidoff D. Doses to brain, skull, and thyroid, following x-ray therapy for Tinea capitis. Phys Med Biol 1968;13:247–258.
Ron E, Modan B, Boice JD Jr, et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med 1988;319:1033–1039.
Sadamori N, Shibata S, Mine M, et al. Incidence of intracranial meningiomas in Nagasaki atomic-bomb survivors. Int J Cancer 1996;67:318–322.
Shintani T, Hayakawa N, Hoshi M, et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J Radiat Res (Tokyo) 1999;40:49–57.
Preston-Martin S, Henderson BE, Bernstein L. Medical and dental X rays as risk factors for recently diagnosed tumors of the head. Natl Cancer Inst Monogr 1985;69:175–179.
Rodvall Y, Ahlbom A, Pershagen G, et al. Dental radiography after age 25 years, amalgam fillings and tumours of the central nervous system. Oral Oncol 1998;34:265–269.
Ryan P, Lee MW, North B, McMichael AJ. Amalgam fillings, diagnostic dental X-rays and tumours of the brain and meninges. Eur J Cancer B Oral Oncol 1992;28B:91–95.
Longstreth WT Jr, Phillips LE, Drangsholt M, et al. Dental X-rays and the risk of intracranial meningioma. A population-based case-control study. Cancer 2004;100:1026–1034.
Phillips LE, Frankenfeld CL, Drangsholt M, et al. Intracranial meningioma and ionizing radiation in medical and occupational settings. Neurology 2005;64:350–352.
Preston-Martin S, Paganini-Hill A, Henderson BE, et al. Case-control study of intracranial meningiomas in women in Los Angeles County, California. J Natl Cancer Inst 1980;65:67–73.
Hu J, Little J, Xu T, et al. Risk factors for meningioma in adults: a case-control study in northeast China. Int J Cancer 1999;83:299–304.
Ryan P, Lee MW, North B, McMichael AJ. Risk factors for tumours of the brain and meninges: results from the Adelaide adult brain tumor study. Int J Cancer 1992;51:20–27.
Mills PK, Preston-Martin S, Annegers JF, et al. Risk factors for tumours of the brain and cranial meninges in Seven-Day Adventists. Neuroepidemiology 1989;8:266–275.
Schlehofer B, Kunze S, Sachsenheimer W, et al. Occupational risk factors for brain tumours: results from a population-based case-control study in Germany. Cancer Causes Control 1990;1:209–215.
Littorin M, Attewell R, Skerfving S, et al. Mortality and tumour morbidity among Swedish market gardeners and orchardists. Int Arch Occup Environ Health 1993;65:163–169.
Perry A, Gutmann DH, Reifenberger G. Molecular pathogen-esis of meningiomas. J Neurooncol 2004;70:183–202.
Ferrante L, Acqui M, Artico M, et al. Familial meningiomas. Report of two cases. J Neurosurg 1987;31:145–151.
McDowell JR. Familial meningioma. Neurology 1990;40:312–314.
Pulst SM, Rouleau GA, Marineau C, et al. Familial meningi-oma is not allelic to neurofibromatosis 2. Neurology 1993;43:2096–2098.
Maxwell M, Shih SD, Galanopoulos T, et al. Familial menin-gioma: analysis of expression of neurofibromatosis 2 protein Merlin. Report of two cases. J Neurosurg 1998;88:562–569.
Mark J, Levan G, Mitelman F. Identification by fluorescence of the G chromosome lost in human meningiomas. Hereditas 1972;71:163–168.
Zankl H, Zang K. Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. Humangenetik 1972;14:167–169.
Peyrard M, Fransson I, Xie YG, et al. Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. Human Mol Genet 1994;3:1393–1399.
Lekanne Deprez RH, Riegman PH, Groen NA, et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 1995;10:1521–1528.
Schmitz U, Mueller W, Weber M, et al. INI1 mutations in meningiomas at a potential hotspot in exon 9. Br J Cancer 2001;84:199–201.
Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791–800.
Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515–521.
Gusella JF, Ramesh V, MacCollin M, Jacoby LB. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta 1999;1423:M29–36.
Ruttledge MH, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994;6:180–184.
Harada T, Irving RM, Xuereb JH, et al. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996;84:847–851.
Papi L, De Vitis LR, Vitelli F, et al. Somatic mutations in the neurofibromatosis type 2 gene in sporadic meningiomas. Hum Genet 1995;95:347–351.
Wellenreuther R, Kraus J, Lenartz D, et al. Analysis of the neu-rofibromatosis 2 gene reveals molecular variants of meningi-oma. Am J Pathol 1995;146:827–832.
Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495–1500.
Robb VA, Li W, Gascard P, et al. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R, in meningioma pathogen-esis. Neurobiol Dis 2003;13:191–202.
Surace EI, Lusis E, Murakami Y, et al. Loss of tumor suppressor in lung cancer–1 (TSLC-1) expression in meni-ngioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol 2004;63:1015–1027.
Buschges R, Ichimura K, Weber RG, et al. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002;12:145–153.
Cai DX, Banerjee R, Scheithauer BW, et al. Chromosome 1 p and 14 q FISH analysis in clinicopathologic subsets of menin-gioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001;60:628–636.
Cai DX, James CD, Scheithauer BW, et al. PS6K amplification characterizes a small subset of anaplastic meningiomas. Am J Clin Pathol 2001;115:213–218.
Lamszus K, Kluwe L, Matschke J, et al. Allelic losses at 1 p, 9 q, 10 q, 14 q and 22 q in the progression of aggressive menin-giomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999;110:103–110.
Ozaki S, Nishizaki T, Ito H, Sasaki K. Comparative genomic hybridization analysis of genetic alterations associated with malignant progression of meningioma. J Neuro-Oncol 1999;41:167–174.
Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 1997;94:14719–14724.
Watson MA, Gutmann DH, Peterson K, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am J Pathol 2002;161:665–672.
Amirjamshidi A, Mehrazin M, Abbassioun K. Meningiomas of the central nervous system occurring below the age of 17: report of 24 cases not associated with neurofibromatosis and review of literature. Childs Nerv Syst 2000;16:406–416.
Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated menin-giomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001;60:994–1003.
Shoshan Y, Chernova O, Juen SS, et al. Radiation-induced meningioma: a distinct molecular genetic pattern? J Neuro-pathol Exp Neurol 2000;59:614–620.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London Limited
About this chapter
Cite this chapter
Link, M.J., Perry, A. (2009). Meningioma Tumorigenesis: An Overview of Etiologic Factors. In: Lee, J.H. (eds) Meningiomas. Springer, London. https://doi.org/10.1007/978-1-84628-784-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-84628-784-8_11
Publisher Name: Springer, London
Print ISBN: 978-1-84882-910-7
Online ISBN: 978-1-84628-784-8
eBook Packages: MedicineMedicine (R0)